The advancement of regenerative technologies demands careful alignment with societal values, legal frameworks, and business viability. Ethical, regulatory, and commercial aspects address questions of patient consent, long-term safety, equitable access, and sustainability of emerging therapies. The global expansion of clinical trials and biotechnological innovation calls for harmonized approval processes and transparent standards. Commercial strategies must balance profitability with public good, encouraging innovation while maintaining accountability. Ethical, regulatory, and commercial aspects also include intellectual property rights, pricing models, and education for both clinicians and patients. Navigating this complex terrain is essential for responsible translation of regenerative science into accessible and ethically sound healthcare solutions.
Title : Eliminating implants infections with nanomedicine: Human results
Thomas J Webster, Interstellar Therapeutics, United States
Title : Biodistribution and gene targeting in regenerative medicine
Nagy Habib, Imperial College London, United Kingdom
Title : Graphene, butterfly structures, and stem cells: A revolution in surgical implants
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, London NW1 0NH, United Kingdom
Title : Precision in cartilage repair: Breakthroughs in biofabrication process optimization
Pedro Morouco, Polytechnic of Leiria, Portugal
Title : Keratin-TMAO wound dressing promote tissue recovery in diabetic rats via activation of M2 macrophages
Marek Konop, Medical University of Warsaw, Poland
Title : Assessing geometric simplifications in vertebral modeling for reliable numerical analysis of intervertebral discs
Oleg Ardatov, Vilnius University, Lithuania